Patent ID: 8383123

Claim:
A method for treatment of cancer associated with dysregulation of HEPSIN expression, the method comprising administering to a patient in need thereof an effective amount of an antibody for treatment comprising (a) heavy chain hypervariable region (HC-HVR) 1, HC-HVR2, and HC-HVR3 sequences, and (b) light chain hypervariable region (LC-HVR) 1, LC-HVR2 and LC-HVR3 sequences of an antibody produced by hybridoma cell line deposited at American Type Culture Collection (ATCC) under Accession No. PTA-7469, PTA-7470, PTA-7471, PTA-7472 or PTA-7473, wherein said antibody for treatment binds human HEPSIN and is linked to a heterologous agent, and wherein the heterologous agent is a therapeutic agent, cytotoxic agent, or radioisotope.